Primer: China Resources Pharmaceutical Group (3320 HK) - Aug 2026
Integrated Business Model Provides Stability: China Resources Pharmaceutical's vertically integrated model, spanning manufacturing,...
98 Views
APAC Healthcare Weekly (November 16) – Leads Bio, Henlius Bio, Otsuka, ABL Bio, Boryung, Eubiologics
Henlius got FDA approval for Perjeta biosimilar. Otsuka reports positive Phase 3 trial result for sibepernlimab. ABL Bio signed deal with Lilly....
601 Views
The Heat Is On: News Flow and Sentiment in CHINA / HONG KONG (September 11)
HSTECH index is showing increasing strength as Hong Kong continues it Secular Bull Market. Continued strong market breadth indicates both...
817 Views
APAC Healthcare Weekly (Aug 24) – Wuxi Bio, Ab&B Bio, Ascletis Pharma, Remegen, Daiichi Sankyo, CSL
Wuxi Bio got EMA nod for Ireland manufacturing facility. Daiichi Sankyo got breakthrough therapy designation for its drug candidate in US. CSL...
698 Views
The Impact of Trump's Tariffs on China Healthcare - The Victims, And the Safe Haven Assets
As tariff war is heating up, some sectors in China healthcare will be victims, but there will also safe haven assets.The logic behind tariffs is to...
508 Views